

FOR IMMEDIATE RELEASE**SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer**

Cambridge, Mass. – MAY 5, 2014 – SAGE Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the appointment of Thomas D. Anderson as chief commercial strategy officer. Mr. Anderson, former senior vice president, corporate strategy and commercial assessment at Shire plc, brings to SAGE more than 25 years of experience in the life science and healthcare-focused consumer packaged goods industries, with deep commercial expertise in the CNS field.

“Tom’s strong leadership experience and extensive background developing and commercializing therapeutics for the treatment of CNS disorders will help SAGE strategically guide our pipeline of therapies from the clinic to patients in need,” said Jeff Jonas, M.D., chief executive officer of SAGE Therapeutics. “The lead compound in our portfolio of potential seizure medicines, SAGE-547, is currently in a Phase 1/2 trial for the treatment of a life-threatening seizure disorder, super-refractory status epilepticus (SRSE). We look forward to benefitting from Tom’s perspective and know-how as we continue to develop SAGE-547 and other programs for rare CNS disorders.”

Prior to joining SAGE, Mr. Anderson served as senior vice president, corporate strategy and commercial assessment at Shire plc and served as general manager for several of Shire’s psychiatry and neurology products. In addition, he led Shire’s specialty pharmaceutical’s commercial operations, business information and strategic marketing functions and played a lead role in business development efforts. Prior to Shire and in two separate tenures, he spent 17 years in Johnson & Johnson’s pharmaceutical companies, notably Janssen and Ortho-McNeil, where he held senior-level roles in marketing, marketing research, sales and sales management, operations and engineering. In between employments at Johnson & Johnson, he was president and chief executive officer of Ranir Corporation, a dental products company, and executive vice president and chief operating officer of Lander Co., Inc., a healthcare-related consumer packaged goods company, and was a corporate officer and director at both companies. Mr. Anderson received his B.S. in civil engineering from Lehigh University and his MBA in finance from the University of Notre Dame.

“By targeting the GABA_A and NMDA pathways, SAGE Therapeutics is taking a potentially promising approach to addressing rare CNS disorders with a dire need for new therapies, such as SAGE-547,” said Mr. Anderson. “I look forward to partnering with the team at SAGE to potentially deliver SAGE-547 and other new medicines to patients with life-threatening, rare CNS disorders.”

About SAGE Therapeutics

SAGE Therapeutics is a biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE’s lead

program, SAGE-547, is in clinical development for SRSE and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's robust chemistry platform has generated multiple new compounds that target the GABA_A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. SAGE Therapeutics is a private company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors. For more information, please visit www.sagerx.com.

###

Media Contact:

Dan Budwick, Pure Communications
dan@purecommunicationsinc.com
973-271-6085